Jeffrey S. Borer, M.D.
Professor of Medicine, Cell Biology, Radiology and Surgery
Director, The Howard Gilman Institute for Heart Valve Diseases and the
Schiavone Cardiovascular Translational Research Institute
Formerly Chief, Division of Cardiovascular Medicine, 2008-2015
Formerly Chairman, Department of Medicine 2009-2013
State University of New York Downstate Medical Center
Adjunct Professor of Cardiovascular Medicine in Cardiothoracic Surgery
Weill Medical College of Cornell University
New York City
Jeffrey Borer is Professor of Medicine, Cell Biology, Radiology and Surgery at SUNY Downstate Medical Center. For 7 years he served as Chief, Division of Cardiovascular Medicine, simultaneously serving 4 years as Chairman, Department of Medicine, administrative positions he relinquished to direct two research institutes at Downstate. He received a BA from Harvard, M.D. from Cornell, trained at the Massachusetts General Hospital, spent 7 years at the NIH and a year at Guy’s Hospital (London) as Senior Fullbright Hays Scholar. For 30 years he was Gladys and Roland Harriman Professor of Cardiovascular Medicine at Cornell. His major contributions have been in developing stress radionuclide cineangiography, defining criteria for intervention in coronary and valvular diseases and elucidating the role of therapeutic heart rate modulation in heart failure. He has published almost 500 scientific papers and 6 books and has received numerous recognitions and awards.
Carolyn Lam Su Ping
MBBS, MRCP, MS, FACC, FESC
Senior Consultant of the National Heart Centre, Singapore
Associate Professor of Duke-NUS Cardiovascular Academic Clinical Program
Chairperson of the Asia Pacific Association of Women’s Cardiovascular Disease
A graduate from the Faculty of Medicine, National University of Singapore, completed advanced specialty training in Cardiology in Singapore, Dr. Lam pursued her Research Fellowship at the Cardiorenal Laboratory, Heart Failure Fellowship at the Division of Cardiovascular Diseases, and Advanced Cardiology and Master of Biomedical Sciences at Mayo Clinic, Rochester MN. She further obtained training in clinical and genetic epidemiology at the Framingham Heart Study in Boston, MA before returning to Singapore in 2010 on the National Medical Research Council’s Clinician Scientist Award.
Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’scardiovascular disease, hemodynamics, echocardiography,biomarkers and clinical trials.
She started the first Heart Failure with Preserved Ejection Fraction Programme and Women’s Heart Health Clinic in Singapore, was awarded the L’Oreal Women In Science Award (2012) for her work in women’s cardiovascular disease, was named an InterAcademy Medical Panel YoungPhysician Leader at the World Health Summit in Berlin (2012), and won the award for the Junior Chamber International (JCI) Ten Outstanding Young Persons of the World for 2014 –Singapore (2014). She is the Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedica l Research Council-funded research platform; and principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study) and a multinational Asian study of patients with heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study). She is on the Executive Committees of several global heart failure trials.
Bertram Pitt (Ann Arbor, USA)
Professor of medicine emeritus at the University of Michigan School of Medicine.
Dr. Pitt obtained his MD degree from the University of Basel in Switzerland in 1959. He subsequently did a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty there until 1977 when he left to direct the division of cardiology at the University of Michigan School of Medicine.
He has been chairman or co-chairman of a number of clinical trials in cardiology including: SOLVD; ELITE I and II; Prevent; Rales and Ephesus. He is currently chairman of the steering committee of the NHLBI TOPCAT trial examining the effect of spironolactone in patients with HF and preserved LV systolic function; co-chairman of the Emphasis-HF trial examining the role of eplerenone in patients with NYHA Class II HF; chairman of BreakDHF; co-chairman of STOP-CKD; co-chairman of Exceed; cochairman of Escape-SHF and EscapeDH F; chairman of a study evaluating the role of an aldostereone synthase inhibitor in patients with HF and is a member of the executive committee of the Accomplish trial. In addition, he serves as the chairman of the DSMB for the NHLBI HF-Action trial and has over 500 articles in peer reviewed journals. Dr. Pitt has been a member of a numerous medical journal editorial boards.
He has also been a member of a number of medical organizations and has served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University.
Faiez Zannad (Nancy, FRA)
Professor of Therapeutics and Cardiology,
Université de Lorraine, France and
Director of the Clinical Investigation Center, InsermCHU of Nancy. www.cic-nancy.fr/cic
He is currently on annual sabbatical leave, acting as advisor to the Tunisian Ministry of Health, with a mission to structure health research. In the last five years, his main professional activities have been in the following areas:
• Structuring of the clinical research infrastructure in France • Roadmap of health research in Tunisia • Contribution to clinical trial science and methodology in CV disease
• Significant contribution in advances in heart failure treatment, through major clinical trials, mainly with mineralocoticoid receptor antagonists (RALES, EPHESUS, EMPHASIS-HF, REMNDER, ARTS), but also with beta-blockers (CIBIS, CAPRICORN), Angio2 receptor blockers (VALIANT, HEAAL); Direct Renin Inhibitors (ASTRONAUT) and vasopressin antagonists (EVEREST), which has led to the approval of new drugs in this area and 80 11th CardioVascular Clinical Trialists Forum • Washington DC 2014 change in international guidelines.
• Specific interest in mechanistic biomarkers in heart failure Results show that fibrosis biomarkers may predict outcome and describe one target mechanism of action of mineralocoticoid receptor antagonists. • First randomized controlled trial of CV prevention in haemodialysis patients (FOSIDIAL). Results show a potential benefit of ACE inhibitor therapy to decrease CV morbidity and mortality in patients with ESRD and left ventricular hypertrophy. Follow up with the statin trial AURORA, which did not show benefit of Rosuvastatin in haemodialysis patients. On-going ALCHEMIST trial of spironolactone in haemodialysis high-risk patients (FOSIDIAL). Pr. Zannad is involved